Gain Therapeutics
$1.85
38
-$0.09-4.64% Thursday 20:00
Statistics
Day High
1.96
Day Low
1.83
52W High
4.34
52W Low
1.41
Volume
518,956
Avg. Volume
863,049
Mkt Cap
66.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19MayExpected
Expected EPS
-0.1425
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-40.82MNet Income
Analyst Ratings
$8.00Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GANX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Biogen
BIIB
Mkt Cap22.63B
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
PTC Therapeutics
PTCT
Mkt Cap5.4B
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Novartis
NVS
Mkt Cap237.61B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
About
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Show more...
CEO
Dr. Khalid Islam Ph.D.
Employees
23
Country
US
ISIN
US36269B1052
Listings
0 Comments
Share your thoughts
FAQ
What is Gain Therapeutics stock price today?▼
The current price of GANX is $1.85 USD — it has decreased by -4.64% in the past 24 hours. Watch Gain Therapeutics stock price performance more closely on the chart.
What is Gain Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gain Therapeutics stocks are traded under the ticker GANX.
Is Gain Therapeutics stock price growing?▼
GANX stock has risen by +1.09% compared to the previous week, the month change is a -29.66% fall, over the last year Gain Therapeutics has showed a +3.35% increase.
What is Gain Therapeutics market cap?▼
Today Gain Therapeutics has the market capitalization of 66.78M
When is the next Gain Therapeutics earnings date?▼
Gain Therapeutics is going to release the next earnings report on May 19, 2026.
What were Gain Therapeutics earnings last quarter?▼
GANX earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.14 USD resulting in a +23.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Gain Therapeutics revenue for the last year?▼
Gain Therapeutics revenue for the last year amounts to 0 USD.
What is Gain Therapeutics net income for the last year?▼
GANX net income for the last year is -40.82M USD.
How many employees does Gain Therapeutics have?▼
As of April 03, 2026, the company has 23 employees.
In which sector is Gain Therapeutics located?▼
Gain Therapeutics operates in the Health Care sector.
When did Gain Therapeutics complete a stock split?▼
Gain Therapeutics has not had any recent stock splits.
Where is Gain Therapeutics headquartered?▼
Gain Therapeutics is headquartered in Bethesda, US.